Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of JMBI-001 in MYC-positive advanced solid tumors or relapsed/refractory non-Hodgkin lymphoma
CTR20263562Phase 2Active
- Sponsor
- Anticancer Bioscience
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of JMBI-001 in Nonhematologic neoplasms, non-Hodgkin lymphoma (NHL), sponsored by Anticancer Bioscience. Started Sep 2026; status: active.
02
Drugs
JMBI-001
03
Conditions
Nonhematologic neoplasmsnon-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on CTR20263562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263562.